Impact of Human Papillomavirus Vaccination in Reducing Cancer
| Autor: | Margot Savoy, Mina S. Khan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Parents
Pediatrics medicine.medical_specialty Health Knowledge Attitudes Practice Vaccination Coverage Uterine Cervical Neoplasms HPV vaccines Global Health 03 medical and health sciences 0302 clinical medicine Drug Development Neoplasms Health care medicine Humans Pharmacology (medical) 030212 general & internal medicine Papillomavirus Vaccines Human papillomavirus Cervical cancer Cultural Characteristics Primary Health Care business.industry Racial Groups virus diseases Cancer medicine.disease Human papillomavirus vaccination United States Vaccination Oropharyngeal Neoplasms Immunization 030220 oncology & carcinogenesis Practice Guidelines as Topic Female business |
| Zdroj: | Primary care. 47(3) |
| ISSN: | 1558-299X |
| Popis: | Human papillomavirus (HPV) is a significant cause of global morbidity and mortality. A nonavalent HPV vaccine is widely available and recommended for routine use at 11 to 12 years old. Older teens and adults though age 45 years also could be offered vaccination. Widespread use of the HPV vaccine appears to impact the rate of infections and cancers. Some parents/teens may hesitate to be vaccinated. The strongest predictor to receiving the vaccine remains a trusted health care professional making a strong recommendation to receive the vaccine. New HPV vaccines are in the pipeline, including therapeutic vaccines to treat HPV-related cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|